Toremifene

Generic Name
Toremifene
Brand Names
Fareston
Drug Type
Small Molecule
Chemical Formula
C26H28ClNO
CAS Number
89778-26-7
Unique Ingredient Identifier
7NFE54O27T
Background

Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like tamoxifen, toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs.
...

Indication

For the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors. Toremifene is currently under investigation as a preventative agent for prostate cancer in men with high-grade prostatic intraepithelial neoplasia and no evidence of prostate cancer.

Associated Conditions
Metastatic Breast Cancer
Associated Therapies
-
Clinical Trials
Related News

Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer

First Posted Date
2014-03-27
Last Posted Date
2016-05-25
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
600
Registration Number
NCT02097459
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, China

Changes in Breast 3D Ultrasound Measurements Using Toremifene

Phase 3
Completed
Conditions
Circulatory; Change
Interventions
Drug: Toremifene
First Posted Date
2011-08-16
Last Posted Date
2011-08-23
Lead Sponsor
Satakunta Central Hospital
Target Recruit Count
20
Registration Number
NCT01417754
Locations
🇫🇮

Porin Lääkäritalo, Pori, Finland

Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer

Phase 3
Withdrawn
Conditions
Risk of Bone Fracture Occurrences
First Posted Date
2010-10-05
Last Posted Date
2013-11-15
Lead Sponsor
GTx
Registration Number
NCT01214291
Locations
🇺🇸

VA Puget Sound, Seattle, Washington, United States

The Effect of Toremifene Treatment to the Magnetic Resonance Imaging (MRI) Findings in Premenstrual Mastalgia

Phase 3
Completed
Conditions
Breast Pain
Interventions
Drug: placebo
Drug: toremifene
First Posted Date
2007-09-26
Last Posted Date
2009-05-13
Lead Sponsor
Satakunta Central Hospital
Target Recruit Count
10
Registration Number
NCT00534846
Locations
🇫🇮

Satakunta Central hospital, department of gynaecology and obstetrics, Pori, Finland

Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer

First Posted Date
2005-12-21
Last Posted Date
2007-09-10
Lead Sponsor
Intarcia Therapeutics
Target Recruit Count
200
Registration Number
NCT00267553

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

First Posted Date
2004-11-23
Last Posted Date
2007-08-23
Lead Sponsor
Intarcia Therapeutics
Target Recruit Count
842
Registration Number
NCT00097344
Locations
🇺🇦

Research Site, Vinnitsa, Ukraine

🇷🇺

Research site, Krasnodar, Russian Federation

Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer

First Posted Date
2004-07-29
Last Posted Date
2013-04-04
Lead Sponsor
ETOP IBCSG Partners Foundation
Target Recruit Count
452
Registration Number
NCT00002529
Locations
🇨🇭

Universitaetsspital, Zurich, Switzerland

🇦🇺

Royal Prince Alfred Hospital, Sydney, Sydney, New South Wales, Australia

🇦🇺

Royal Adelaide Hospital, Adelaide, South Australia, Australia

and more 17 locations

Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer

Phase 3
Terminated
Conditions
Breast Cancer
First Posted Date
2004-05-05
Last Posted Date
2014-03-26
Lead Sponsor
Intarcia Therapeutics
Registration Number
NCT00010322
Locations
🇺🇸

Millennix Inc., Purchase, New York, United States

Toremifene in Treating Patients With Desmoid Tumors

Phase 2
Completed
Conditions
Desmoid Tumor
First Posted Date
2004-04-22
Last Posted Date
2013-07-10
Lead Sponsor
Advocate Lutheran General Hospital
Target Recruit Count
72
Registration Number
NCT00002595
Locations
🇺🇸

Lutheran General Hospital, Park Ridge, Illinois, United States

Toremifene in Treating Patients With Ovarian Cancer

Phase 2
Withdrawn
Conditions
Ovarian Cancer
Interventions
Drug: toremifene
First Posted Date
2003-01-27
Last Posted Date
2017-07-13
Lead Sponsor
George Washington University
Registration Number
NCT00003865
Locations
🇺🇸

George Washington University Cancer Center, Washington, D.C., District of Columbia, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy